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purpose: Elevated uric acid (UA) levels correlate with increased mortality in patients with chronic heart failure (HF) but the association in 
hospitalized HF (HHF) patients is unclear. We investigated the patient characteristics and outcomes associated with baseline UA level in a large 
cohort of HHF patients with ejection fraction (EF) ≤40%.
methods: This analysis of the EVEREST trial included 3,955 patients with baseline UA data. Clinical characteristics and outcomes were compared 
across UA quartiles. Median follow-up was 9.9 months.
results: results: are displayed in the Table. The mean UA level was 9 ±3 mg/dl (range 1-21). Patients with higher baseline UA tended to 
have lower systolic blood pressure and EF and higher natriuretic peptide, serum creatinine and blood urea nitrogen levels. After adjusting for 24 
baseline prognostic factors, higher UA level was associated with increased risk of all-cause death and the composite of cardiovascular mortality or 
hospitalization for HF.
conclusion: In a large population of HHF patients with reduced EF, higher UA level correlated with a high-risk patient profile. Higher UA was 
independently associated with increased risk of mortality and HF hospitalization. Further studies are needed to evaluate UA level as a potential 
target for therapy.
Table - Baseline Patient Characteristics and Outcomes by Baseline Serum Uric Acid Quartile* 
Quartile 1
N=967
Quartile 2
N=1012
Quartile 3
N=977
Quartile 4
N=999 p-value
Baseline serum uric acid range (mg/dl) 1.2-7.0 7.1-8.8 8.9-10.8 10.9-21.0 --
Demographics
Tolvaptan 514 (53) 494 (49) 464 (48) 504 (51) 0.07
Age (years) 67 ±11 66 ±12 65 ±12 65 ±13 <0.01
Male 637 (66) 754 (75) 774 (79) 780 (78) <0.01
Ischemic heart failure etiology 659 (69) 653 (65) 641 (66) 614 (63) 0.03
New York Heart Association class IV 323 (33) 371 (37) 401 (41) 468 (47) <0.01
Baseline Laboratory Values, Co-morbidities and Medications
Systolic BP (mmHg) 125 ±21 122 ±20 120 ±20 115 ±18 <0.01
Heart rate (beats/min) 79 ±15 79 ±16 80 ±16 80.7 ±16 0.02
Ejection fraction (%) 30 ±8 28 ±8 27 ±8 25 ±8 <0.01
B-type natriuretic peptide (pg/mL) 481 (194-1136) 539 (254-1284) 746 (316-1474) 1107 (543-2126) <0.01
Serum creatinine (mg/dL) 1.0 (0.9-1.3) 1.2 (1.0-1.4) 1.3 (1.1-1.6) 1.5 (1.3-1.9) <0.01
Serum urea nitrogen (mg/dL) 20 (17-27) 24 (19-31) 27 (21-35) 35 (26-48) <0.01
Serum sodium (mEq/L) 140 (138-143) 140 (138-142) 140 (137-143) 139 (136-142) <0.01
Hypertension 693 (72) 717 (71) 693 (71) 705 (71) 0.96
Hyperlipidemia 450 (467) 491 (49) 473 (49) 499 (50) 0.55
Coronary artery disease 689 (71) 725 (72) 687 (70) 685 (69) 0.42
Previous myocardial infarction 485 (50) 518 (51) 506 (52) 492 (49) 0.68
Diabetes mellitus 379 (39) 387 (38) 363 (37) 401 (40) 0.56
Chronic kidney disease 137 (14) 216 (21) 280 (29) 421 (42) <0.01
B-blockers 700 (74) 747 (75) 736 (77) 705 (74) 0.32
ACEI/ ARB 826 (87) 860 (87) 822 (86) 759 (80) <0.01
Mineralocorticoid receptor antagonist 544 (57) 635 (64) 583 (61) 550 (58) 0.01
Digoxin 427 (45) 457 (46) 492 (51) 463 (49) 0.02
Outcomes 
All-cause mortality 180 (19) 212 (21) 257 (26) 391 (39) <0.01
CV mortality 136 (14) 158 (16) 211 (22) 296 (30) <0.01
HF hospitalization 192 (20) 245 (24) 283 (29) 377 (38) <0.01
CV hospitalization 291 (30) 367 (36) 388 (40) 485 (49) <0.01
CV mortality or HF hospitalization 293 (30) 362 (36) 425 (44) 547 (55) <0.01
CV mortality or CV hospitalization 354 (37) 445 (44) 478 (49) 603 (60) <0.01
Outcomes - Adjusted Hazard Ratios and 95% Confidence Intervals (referent Quartile 4)
All-Cause mortality 0.75 (0.62-0.91) 0.82 (0.68-0.98) 0.88 (0.74-1.04) --
CV mortality or hospitalization for HF 0.72 (0.62-0.85) 0.81 (0.70-0.94) 0.91 (0.80-1.04) --
*Values expressed as mean +/- SD, median (25th, 75th percentile) or n (%). 
